← Back to headlines
Citi Initiates Alnylam Pharmaceuticals with Buy Rating
Citi has begun coverage of Alnylam Pharmaceuticals (ALNY) with a 'Buy' rating, signaling a positive investment recommendation for the biotech company.
25 May, 18:09 — 25 May, 18:09
Sources
Showing 1 of 1 sources
Related Stories
Diversified Energy to Acquire Elliott-Backed Birch Energy for $1.8 Billion
25m ago
Emergency Landing of Plane Carrying US Homeland Security Chief Mullin
27m ago
Berkshire Hathaway Signals Long-Term Commitment to Japanese Trading Houses
53m ago
South Korean Utility Proposes $15 Billion Upfront Power Payment From Samsung
1h ago